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LAY SUMMARY 
This study examines the impact of liver transplantation in primary sclerosing 
cholangitis (PSC) with organs donated after circulatory death (DCD), compared to 
donation after brainstem death (DBD). We show that in appropriately selected 
patients, the outcomes for DCD transplantation mirror those using DBD livers, with 
no significant differences in complication rate, patient survival or transplanted liver 
survival. In an era of organ shortage and increasing wait-list times, DCD livers 
represent a potential treatment option for transplantation in PSC. 
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ABSTRACT 
 
Background and aim: Primary sclerosing cholangitis (PSC) is a progressive fibro-
inflammatory cholangiopathy for which liver transplantation is the only life-extending 
intervention. These patients may benefit from accepting liver donation after 
circulatory death (DCD), however their subsequent outcome is unknown.  
Methods: Clinical outcomes were prospectively evaluated in PSC patients 
undergoing transplantation from 2006 to 2016 stratified by donor type (DCD, n=35 
vs. donation after brain death [DBD], n=108). 
Results: In liver transplantation for PSC; operating time, days requiring critical care 
support, total ventilator days, incidence of acute kidney injury, need for renal 
replacement therapy (RRT) or total days requiring RRT were not significantly 
different between DCD vs. DBD recipients. Although the incidence of ischaemic-type 
biliary lesions was greater in the DCD group (incidence rate [IR]: 4.4 vs. 0 cases/100-
pt.-yrs; p<0.001) there was no increased risk of post-transplant biliary strictures 
overall (hazard ratio [HR]: 1.20, 0.58–2.46; p=0.624), or in sub-analysis specific to 
anastomotic strictures or recurrent PSC, between donor types. Graft loss and mortality 
rates were not significantly different following transplantation with DCD vs. DBD 
livers (IR: 3.6 vs. 3.1 cases/100-pt.-yrs, p=0.34; and 3.9 vs. 4.7, p=0.6; respectively). 
DCD liver transplantation in PSC did not impart a heightened risk of graft loss (HR: 
1.69, 0.58–4.95, p=0.341) or patient mortality (0.75, 0.25–2.21, p=0.598).  
Conclusion: Transplantation with DCD (vs. DBD) livers in PSC does not impact 
graft loss or patient survival. In an era of organ shortage, DCD grafts represent a 
viable therapeutic option for liver transplantation in PSC patients. 
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INTRODUCTION 
 
Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory 
cholangiopathy stigmatised by a disproportionate impact on young patients [1,2]. 
Presently, liver transplantation is the only proven life-extending intervention, and 
PSC now accounts for 10 – 15% of all liver transplant activity within Europe [3–5]. In 
parallel, the overall number of patients with chronic liver disease on an active liver 
transplant register is increasing globally [4–6], without an appropriate rise in the 
donor pool [7]. A challenge more specific to PSC, is that patients may suffer 
complications inadequately represented by the model for end-stage liver disease 
(MELD) score; such as intractable pruritus, recurrent ascending cholangitis, and 
reduced overall quality of life [8]. Consequently, the number of PSC patients who die 
or are withdrawn from a transplant waiting list due to clinical deterioration is rising, 
and now approximates 20% [9]. This group of invariably young individuals may have 
their life saved in the event of timely donor availability. 
 
Donation after brain death (DBD) is the practice of choice in liver transplantation, 
although the increasing demand for organs has furthered interest in using grafts 
donated after circulatory death (DCD). Indeed, the advances in graft preservation, 
immunosuppression and operative techniques have significantly improved clinical 
outcomes following DCD grafting [10]. However, DCD livers are still used prudently 
[11], given the risk of acute kidney injury (AKI) and ischaemic type biliary lesions 
(ITBL) [12–16]. The latter are defined radiologically, as biliary strictures and 
dilatations occurring in the absence of hepatic artery stenosis or thrombosis, portal 
thrombosis, chronic ductopenic rejection, and recurrent PSC [14,17]; and associated 
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clinically with significant patient morbidity, a need for multiple biliary interventional 
procedures and repeated hospital admissions [12,18].  
 
The precise pathogenic mechanisms leading to ITBL are unknown, but postulated to 
involve ischaemia reperfusion injury (IRI), microvessel thrombosis and impaired 
cholangiocyte regeneration [14]. In transplantation for PSC more specifically, we also 
observe a high incidence of post-transplant biliary strictures attributable to recurrent 
disease [19,20]. Development of the latter has also been attributed to poor quality in 
donor organs [21,22],  and a proposal that IRI itself can lead to a de novo autoimmune 
cascade and recurrence of PSC in the transplanted liver. Such hypothesis suggests 
existence of a common mechanistic pathway in the pathogenesis of biliary strictures 
post liver transplantation [21,23]. Furthermore, cholangiographic features of ITBL 
and recurrent PSC cannot be easily distinguished, and often reported collectively as 
non-anastomotic stricturing disease [19]. 
 
The University Hospitals Birmingham NHS Foundation Trust (UHB) contributes 25% 
of all liver transplant activity in the United Kingdom (UK); and in contrast to several 
other centres, our decline rate for offered DCD liver grafts was only ~20% by 2016 
[5]. We select recipients for a DCD graft who are deemed ‘low-risk,’ for instance 
patients with MELD scores enough to warrant transplantation, but too low to reach 
priority on the waiting list. This contrasts to institutional policy elsewhere, wherein 
high MELD scoring patients are preferentially selected due to the survival benefit 
from early transplantation being greatest for this group [24–26]. However, our 
experience as well as that of certain others, is that patients having a low MELD score 
are more likely to achieve survival benefit with a DCD liver compared to prolonged 
transplant wait-list times; whereas those with a high-risk phenotype experience an 
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increased rate of graft failure and post-transplant complications [10,27,28]. 
Furthermore, all DCD retrievals are derived from controlled donors (Maastricht III) 
[29] and we have shown that with appropriate recipient selection and maintaining low 
ischaemic times, DCD livers yield outcomes similar to DBD transplantation [10]. 
Nevertheless, liver transplantation for PSC across many centres is restricted to the 
usage of DBD grafts [19], due to apprehensions of post-transplant biliary 
complications. Given that the incidence of PSC is rising [30], while the prevalence of 
an ‘ideal’ donation pool continues to decline, the usage of liver grafts arising from 
DCD donors seems unavoidable in clinical practice. Thus, the aim of this study was to 
determine the clinical impact of using liver grafts donated after circulatory death in 
patients specifically undergoing transplantation for PSC. 
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PATIENTS AND METHODS 
 
Study population 
We reviewed a prospectively collected, well-characterised database of all adult 
patients undergoing liver transplantation since the date of our first DCD transplant in 
a PSC patient (February 2006) and up until January 2016. The hospital transplant 
database is maintained prospectively and contains information on the donor, the 
recipient, the retrieval process, the peri-operative period, complications and follow-
up, as detailed elsewhere [10]. In order to ensure robustness, accuracy and 
completeness of data for our PSC cohort, the transplant database was cross-referenced 
with an independently accrued registry of all patients having previously attended or 
under current follow-up of the Birmingham PSC clinic since September 1983. Only 
patients transplanted between 2006 and 2016 were selected for this study. 
 
Clinical endpoints 
The ‘time-dependent’ clinical endpoints for our study were as follows: 
A)  Graft loss and patient mortality (primary study endpoint).  
B)  Primary vascular injury; specifically hepatic artery thrombosis (HAT) and hepatic 
artery stenosis (HAS) – evident on contrasted computed tomography (CT), 
magnetic resonance imaging (MRI) or dedicated angiography. 
C)  Biliary stricturing disease; with sub-analysis specifically for non-anastomotic 
strictures – evident on cholangiography (either magnetic resonance or endoscopic 
retrograde cholangiopancreatography; MRCP or ERCP, respectively). When 
referring to non-anastomotic biliary strictures collectively, this pertains to lesions 
developing in the absence of ABO incompatibility, chronic rejection or hepatic 
artery compromise, i.e. focussing on ITBL and recurrent PSC. 
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The need and type of interventions required following development of vascular or 
biliary complications were classified as endoscopic/radiological, reconstructive 
surgery and need for re-transplantation. Post-operative complications were also 
documented according to the Clavien–Dindo grading system (IIIa and IIIb), and when 
a patient required multiple procedures the level of highest intervention was chosen for 
analysis [31].  
 
Patients were censored at the date of last follow-up if they did not meet the clinical 
endpoint in question. In addition, primary graft non-function, bile leaks or acute 
kidney injury (AKI) were assessed as peri-operative ‘categorical’ endpoints with a 
binary outcome measure. The latter was defined with reference to the ‘Risk, Injury, 
Failure, Loss, End-stage kidney disease’ (RIFLE) criteria [32]. 
 
Statistical analysis 
Data are presented using the median and interquartile range (IQR) for continuous 
variables. The non-parametric Mann-Whitney U-test was used to determine whether 
significant differences existed between groups. Differences in nominal data were 
compared by Fisher’s exact test. A p value of <0.05 was deemed statistically 
significant.  
 
Clinical outcomes’ analysis was performed through Kaplan-Meier survivorship 
estimates, and significant differences between groups assessed by Log-rank testing. 
The proportion of clinical events are presented as cumulative incidence (%) and as 
incidence rates (IR) per 100-patient-years with respective confidence intervals (95% 
CI). Additionally, Cox proportional hazards models were fit in order to assess the 
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impact of individual covariates on the instantaneous rate of respective events (hazard 
ratios [HR]. All data were analysed using IBM® SPSS® v.23.0 (Armonk, NY: IBM 
Corp.) 
 
Completeness, plausibility and validity of the data were independently verified (by 
PJT, IS, RL and ES), including personalised objective review of all historical medical 
charts. Local regulatory board approval was obtained prior to study initiation and 
database/chart review (CAB-04186-12 and CARMS-02246). 
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RESULTS 
 
Characteristics of the patient population 
Over a ten-year period, 143 patients with PSC undergoing transplantation at our unit 
received either a DBD or DCD liver graft. The majority were men (71.3%), with a 
median age at time of transplant of 49 years (IQR: 35 – 60), and a pre-existing history 
inflammatory bowel disease (IBD; 70.6%) (Supplementary Table 1). Observing this 
cohort in its entirety, 34 patients experienced a clinically significant episode prior to 
the end of our study; specifically graft loss (n=16) and/or death (n=22), yielding a 
cumulative follow-up till first clinical event of 457-patient-years (IR: 7.45, 95% CI: 
6.60 – 8.82 events per 100-patient-years).  
 
Peri-operative course of PSC-DCD versus PSC-DBD liver transplant recipients 
Within our PSC cohort, 35 patients received liver donation after circulatory death. 
Characteristics were similar between DBD and DCD groups, although recipients of 
the latter were observed to have lower MELD scores, shorter warm ischaemic times 
(WIT / implantation time) and shorter donor cold ischaemic times (CIT) 
(Supplementary Table 1). The median donor functional warm ischaemic time for 
DCD livers was 20 minutes.  
 
Comparing donor groups, there were no significant differences in the median duration 
of surgery, transfusion requirements, duration of intensive care unit (ICU) stay or 
duration of hospital stay in total. Post-operative bile leaks were more common in 
recipients of a DCD liver, who also trended an increased risk of renal injury. These 
differences were not, however, statistically significant, even after restricting the 
analysis to transplantation using non-split livers (Table 1). 
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Transplantation in PSC is associated with a high incidence of vascular events 
Overall, 24.5% of PSC patients (n=35) developed a vascular complication post-
transplantation; with a heightened risk in DCD recipients that reached statistical 
significance when excluding split donor grafts (vs. all DBD grafts, HR: 1.77, 0.88 – 
3.57, p=0.110; vs. non-split DBD grafts only, HR: 2.52, 1.16 – 5.46, p=0.020). 
Vascular complications were predominantly hepatic artery stenosis or hepatic artery 
thrombosis (Supplementary Table 2 and Supplementary Figure 1), with lesser 
contribution from isolated cases of hepatic artery aneurysms, portal vein stenosis, and 
branch portal vein occlusion (data not shown).  
 
We observed that approximately 9% of all transplanted PSC patients developed HAT 
irrespective of donor type, with the highest incidence in those having pre-existing 
IBD (Supplementary Figure 2). However, the risk of developing HAT was not 
significantly greater in DCD vs. DBD donor types (HR: 1.09, 0.30 – 4.00, p=0.895) 
even after excluding transplantation utilising split liver grafts (HR: 1.23, 0.32 – 4.80, 
p=0.767). 
 
Incidence of post-transplantation biliary strictures is independent of donor type 
In our PSC cohort, 31.5% of transplanted patients (n=45) developed recurrent biliary 
strictures, 6 of which were attributed to hepatic artery stenosis (DBD=3 vs. DCD=3, 
p=0.157); with the remainder unrelated to vascular injury (Supplementary Table 3, 
Figure 1, Figure 2 and Figure 3).  
 
Approximately 15% of PSC patients underwent biliary reconstruction via duct-to-duct 
anastomosis, which was associated with a shorter median operating time compared to 
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choledochojejunostomy (4.2 [3.4 – 4.8] hrs. vs. 5.0 [4.1 – 5.8] hrs. p=0.033). In all 21 
cases, the choice of duct-to-duct anastomosis was made when the recipient biliary tree 
was free from extra-hepatic disease, including 2 patients with significant bowel wall 
oedema, 1 individual with prior small bowel resection (due to Crohn’s disease) and 2 
with extensive intra-abdominal adhesions. No patient with duct-to-duct anastomosis 
developed post-transplant biliary malignancy. 
 
The incidence of non-anastomotic biliary strictures overall (NAS), as well as event-
free survival at 6- and 12-months was not significantly different when stratified by 
donor type (Figure 1). Although duct-to-duct anastomoses were more common in our 
DCD group (Table 1), this did not confer an increased risk of NAS (Supplementary 
Figure 3A and B). Reciprocally, there was no increased risk of developing NAS in 
patients with a Roux-en-Y choledochojejunostomy in DCD vs. DBD transplantation 
(Supplementary Figure 3C and D). 
 
Observing our PSC cohort in its entirety, NAS were most often classified as disease 
recurrence if manifest following DBD transplantation (16.7%), compared to ITBL in 
DCD recipients (11.4%) (Supplementary Table 3). Whilst the incidence of ITBL 
was significantly greater using DCD livers (Figure 2 and Figure 3) the overall risk of 
developing any post-transplantation biliary stricture (HR: 1.20, 0.58 – 2.46, p=0.624), 
in addition to the number of patients needing intervention, was not significantly 
greater when compared with DBD grafts (Supplementary Table 3 and 
Supplementary Table 4). 
 
Non-anastomotic biliary strictures in keeping with ITBL (n=4) developed within the 
first year following transplantation, with a median time-to-event of 116 days in the 
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affected group; range 27 – 371 days. By contrast, patients who developed recurrent 
PSC (n=20) demonstrated a significantly longer median time-to-event of 871.5 days; 
range 118 – 2163 days (p=0.018; Mann-Whitney test). No incidence of recurrent PSC 
developed within 90 days, and the only 2 cases diagnosed in our DCD group were 
identified at 427 days and 1083 days after transplantation. Amongst the total group 
with NAS (n=24), Histopathological assessment was available for 10 patients; 
including all who manifest early biliary lesions in the post-transplant course (within 6 
months) despite receiving a DBD liver. In all of the latter, histology supported a 
diagnosis of PSC recurrence; complementary to clinical suspicion, timing of onset of 
biliary strictures and cholangiographic assessment.  
 
Graft loss and patient mortality rates are similar for DCD versus DBD recipients 
With regard to our primary endpoint, we observed no significant differences in graft 
or patient survival times between donor types, even after excluding recipients of split 
livers (Table 2 and Figure 4). Notably, there was no increased risk of graft loss (HR: 
1.69, 95% CI: 0.58 – 4.95; p=0.341), mortality risk (HR: 0.75, 95% CI: 0.25 – 2.21; 
p=0.598), or graft loss/mortality as a combined endpoint (HR: 1.24, 95% CI: 0.56 – 
2.66; p=0.583) with DCD versus DBD liver transplantation in PSC (Table 2).  
 
Outcomes for DCD transplantation in PSC are akin to non-PSC DCD recipients 
Next, we compared the post-transplant outcomes in our PSC cohort versus that 
observed for other aetiologies (Supplementary Table 5 and Supplementary Table 
6). The overall rate of graft loss was greater following liver transplantation for PSC 
(Table 3 and Supplementary Figure 4), albeit with no significant differences in 
patient mortality, or graft loss/mortality as a combined endpoint.  
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The proportion of patients developing HAT was greater in our PSC vs. non-PSC liver 
transplant cohort (9.1% vs. 4.8%, respectively; p=0.046). However, the incidence was 
not significantly different between DCD recipients of PSC vs. non-PSC aetiology (IR: 
3.4 [95% CI: 2.6 – 5.3] vs. 3.0 [95% CI 2.6 – 3.4]; p=0.775). Although the incidence 
of NAS (overall) was similar between PSC DCD vs. non-PSC DCD cohorts, a 
proportionally greater event rate was observed in PSC patients when restricting 
analysis to lesions manifesting after the first 12 months following transplantation 
(Supplementary Figure 5A), indicative of the burden of recurrence. However, the 
incidence rate of ITBL, specifically, was not significantly different between groups 
receiving a DCD liver (Supplementary Figure 5A). 
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DISCUSSION 
 
Herein, we describe the clinical course following liver transplantation across a 
contemporary cohort of PSC patients stratified by donor type; specifically DCD 
versus DBD graft recipients. In so doing, we found no significant differences in 
transfusion requirement, need for organ support post-transplant, or length of hospital 
stay between groups. Whilst the incidence of ITBL was heightened in DCD 
recipients, the risk of AKI, HAT, or biliary strictures overall, was not significantly 
increased when compared with the DBD group over time. Perhaps most apparent, was 
the finding that DCD versus DBD transplantation did not adversely affect recipient or 
graft survival in PSC; and whilst the rate of graft loss was significantly greater 
compared to non-PSC patients, this was not confined to a particular donor type. 
 
As an aetiology of chronic liver disease, the burden of PSC on younger patients is 
substantial, with a median age of transplantation below 50 years. Thus, there is a need 
to maximise the number of ‘life-years’ gained after transplantation, and clinicians 
who manage PSC strive to provide patients with the best graft possible. Unfortunately 
the divide between an optimum donation pool and the number of patients who require 
liver transplantation is increasing. The transplant community must therefore capitalise 
on the reach of DCD grafts in response to the rising burden not just of PSC [30], but 
also of chronic liver disease in general [33]. In the UK, the number of patients on the 
active liver transplant register has more than doubled in the last ten years, and in 
response there has been an exponential rise in the usage of DCD grafts [5,6]. 
Conversely, the United Network for Organ Sharing (UNOS) database from North 
America indicates that donation after circulatory death increases the odds of liver 
non-use by four-fold [11]. The increasing reluctance to use DCD livers largely 
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reflects the perception that post-transplant outcomes are worse, in particular the 
development of ITBL [12–14,24,34,35].  
 
Such apprehensions may be heightened particularly in patients with PSC, who 
harbour an additive risk of post-transplant biliary strictures related to recurrent disease 
[19–21]. The morphological features of recurrent PSC are often difficult to 
distinguish from biliary strictures due to ITBL, and presently there is no single 
diagnostic tool permitting accurate differentiation with absolute certainty. In addition 
to the impact of marginal donor organ quality [14], ITBL develops most commonly in 
the first 6 – 12 months following transplantation [36]. This contrasts with reports of 
PSC recurrence, which tends to manifest after the first year [37]. Histopathology may 
also complement clinical and radiological suspicion; for instance, widespread 
ulceration and necrosis of the large bile duct branches as well as arteriolonecrosis are 
described for ITBL, but such features are infrequent in PSC [38,39]. 
 
With these caveats in mind, we observed no significant difference in incidence of 
NAS overall between PSC DBD vs. PSC DCD patients across multiple time points. 
However, strictures that were felt more in keeping with ITBL developed exclusively 
in the first 12 months and concordant with receiving a DCD liver. In any event the 
number requiring interventional procedures – a major determinant of quality of life – 
was similar between donor groups, even in a sub-analysis of intervention type. This 
has implications for the appropriate counselling of patients who are at risk of 
developing post-transplant stricturing disease, although longer-term, multi-centre 
studies are required to validate our experience. 
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The traditional method of biliary anastomosis in liver transplantation for PSC is 
Roux-en-Y choledochojejunostomy [40]; and whilst some investigators report success 
with choledochoduodenostomy, the approach is not universally favoured given 
concerns over duodenal leaks and overall biliary complications [41,42]. Additionally, 
21 patients in our cohort underwent duct-to-duct biliary reconstruction and in all cases 
this was when the recipient common bile duct was free of visible disease. Historically, 
duct-to-duct anastomosis was not opted for in PSC transplantation given the perceived 
risk of recurrent biliary strictures [40], and theoretically, malignant degeneration. 
However, more contemporary data including that from meta-analyses indicate there is 
no increased risk when compared to Roux-en-Y choledochojejunostomy [43–47]; 
findings validated convincingly in our study. Duct-to-duct anastomosis more 
effectively restores the natural anatomy and function of the biliary tree, maintains 
normal sphincter function (putatively reducing the incidence of cholangitis episodes), 
and facilitates easier accessibility to the bile ducts by ERCP post-transplant. This is 
highly relevant for PSC patients, given the incidence with which NAS occur. By 
contrast, there may arise circumstances wherein Roux-en-Y anastomosis is less 
favourable, for instance in patients with previous surgery resulting in a shortened 
small bowel, extensive intra-abdominal adhesions, small bowel oedema due to portal 
hypertension, or if there has been prolonged portal vein clamping during the 
transplant procedure.  
 
Pathophysiological understanding of non-anastomotic biliary stricturing is 
incomplete, although the risks for developing ITBL and recurrent PSC are probably 
linked to donor graft quality and factors inherent to the recipient, respectively. 
However, overlapping mechanistic insults have been proposed, including putative 
micro-angiopathic aetiology and a ‘toxic bile’ hypothesis [14,23,48–50], illustrating 
  
 20
how a multitude of biologic pathways result in a common phenotypic manifestation.  
In any event, no evidence-based therapy has been consistently proven to improve 
graft survival for either entity, and re-transplantation may be indicated for both. 
Whilst it can be argued that management strategies should differ, our threshold for 
intervention (including the need for re-transplantation) remains driven by the 
extent/distribution of biliary stricturing, severity of graft dysfunction, and/or the 
burden of recurrent biliary sepsis; not whether strictures are formally labelled as ITBL 
or PSC recurrence. 
 
With regard to clinical outcome, the literature presents a conflicting picture, with 
multi-centre registries indicating a relatively high graft failure rate with DCD livers 
[34,35]; whereas smaller, yet ‘high-volume’ single-centre studies indicate similar 
graft and patient survival following DBD transplantation [10,51–53]. Furthermore, 
meta-analyses of clinical outcomes following DCD liver transplantation highlight a 
significant yet unexplained difference in effect size between individual contributing 
units [13,54]. This may explain our discrepant findings compared with the UNOS 
report, which demonstrated a higher risk of graft loss following DCD transplantation 
in PSC despite maintaining similar donor functional warm ischaemic times (FWIT) 
[22]. Furthermore, DCD retrievals in the UK take place almost exclusively with the 
use of ‘controlled’ retrievals (according to Maastricht criteria), and in our centre 
provided to patients with low MELD scores. This contrasts with certain other 
European countries and the United States, where both controlled and uncontrolled 
DCD retrievals may be utilised [55].  
 
Notably, a greater incidence of graft loss was observed in PSC patients overall, 
despite this group having more favourable donor and recipient characteristics than 
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their non-PSC counterparts; including younger donor and recipient age, lower donor 
and recipient body mass index (BMI), and shorter WIT and CIT. These findings 
suggest a more general predisposition to the development of post-transplant vascular 
and biliary injury. However, the incidence rate of HAT with DCD livers was not 
greater for PSC patients, rather increased specifically in the cohort with a history of 
pre-existing IBD. The latter harbours a well recognised association with PSC, and 
also with increased platelet activation and an increased risk of thromboembolism [56]. 
Our study is not without limitation. Despite being the largest single-centre experience 
utilising DCD liver transplantation in PSC patients, external independent and 
prospective validation is of critical importance. Additionally, the lack of protocol 
cholangiographic / angiographic surveillance post-transplantation is caveat across 
most studies determining outcomes following liver transplantation, including those 
from our own centre. In this regard, it is conceivable that the sub-clinical incidence of 
vascular events and biliary strictures was higher than actually reported. Finally, it 
must be recognised that DCD liver transplantation is an evolving practice, and longer-
term patient and graft survival impact have yet to be determined. 
 
In conclusion, the frequency of post-transplant biliary strictures in PSC does not 
significantly differ between donor types, although DCD recipients are more 
prone to early, ischaemic-type biliary lesions. However, overall patient and graft 
survival rates are not significantly different between PSC-DCD and PSC-DBD 
groups. Given the era of organ shortage, DCD liver transplantation represents a 
viable life-extending intervention in an appropriately selected patient 
population. 
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Table 1: Operative, peri-operative and early post-operative characteristics in the PSC liver transplant cohort 
 
All patients 
 
(n=143) 
DBD  
All grafts 
(n=108) 
DBD 
Non-split grafts 
(n=86) 
DCD 
 
(n=35) 
p * 
 
p ** 
Duration of surgery (hrs.) 4.8 (4.1–5.7) 5.0 (4.1–5.7) 4.9 (4.1–6.0) 4.8 (3.9–5.4) 0.213 0.310 
Duct-to-duct anastomosis 21 (14.7%) 12 (11.1%) 10 (11.6%) 9 (25.7%) 0.052 0.095 
Total Transfusion requirements       
Number needing RBC  81 (56.6%) 65 (60.2%) 51 (59.3%) 16 (45.8%) 0.119 0.226 
-Volume (units) 3 (2–4)  2 (2–4) 2 (2–4) 3 (2–5) 0.343 0.264 
Number needing FFP  99 (69.2%) 78 (72.2%) 62 (72.1%) 21 (60%) 0.149 0.203 
-Volume (units) 6 (4–10) 6 (3–10) 6 (4–10) 8 (4–10) 0.248 0.402 
Number needing platelets  51 (35.7%) 40 (37.7%) 32 (37.2%) 11 (31.4%) 0.524 0.676 
-Volume (units) 10 (10–10) 10 (5–13)  10 (8–13) 10 (10–10) 0.652 0.723 
Number needing cryoprecipitate  7 (4.9%) 4 (3.7%) 4 (4.7%) 3 (8.6%) 0.252 0.411 
-Volume (units) 2 (1–2) 2 (2–4) 2 (1–4) 2 (2–2) 0.629 0.629 
Number needing cell saver solution 83 (58.0%) 61 (56.5%) 52 (60.5%) 22 (62.9%) 0.542 0.840 
-Volume (mL) 504 (300–1016) 521 (483–1016) 501 (292–1030) 500 (280–747) 0.248 0.248 
Number needing Trasylol  17 (11.9%) 10 (9.3%) 9 (10.5%) 7 (20.0%) 0.092 0.234 
Primary graft non-function 5 (3.4%) 4 (3.7%) 3 (3.5%) 1 (2.9%) 1.000 1.000 
Bile leaks  13 (9.1%) 7 (6.5%) 5 (5.8%) 6 (17.1%) 0.085 0.077 
Acute kidney injury 
Risk (or above) 76 (53.1%) 53 (49.1%) 47 (54.7%) 23 (65.7%) 0.082 0.233 
Injury (or above) 49 (34.2%) 34 (32.4%) 30 (34.9%) 15 (42.9%) 0.229 0.410 
Failure  21 (14.7%) 13 (12.0%) 11 (12.8%) 8 (22.9%) 0.168 0.172 
Number needing RRT  21 (14.7%) 16 (14.8) 15 (17.0%) 5 (14.3%) 0.923 0.793 
-Days RRT needed 5 (3 – 11) 7 (3–14) 8 (4–15) 5 (4–8) 0.491 0.284 
Days of hospital stay 10 (8–14) 10 (8–13) 10 (8–14) 9 (7–16) 0.768 0.794 
Days on ICU 2 (2–4) 3 (2–4) 3 (2–4) 2 (2–3) 0.251 0.198 
Days requiring invasive ventilation 1 (1–1) 1 (1–2) 1 (1–2) 1 (1–1) 0.064 0.106 
* Denotes statistical comparisons between all DBD vs. DCD liver transplants in PSC patients 
** Denotes statistical comparisons between only whole liver DBD grafts vs. DCD transplants in PSC patients 
 
Data presented as median (IQR) for continuous variables and number (%) for categorical variables. AKI, acute kidney injury; FFP, fresh frozen plasma; ICU, 
intensive care unit; RRT, renal replacement therapy. 
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Table 2: Overall patient and graft survival following liver transplantation in PSC  
 
All patients 
(n=143) 
DBD 
All grafts 
(n=108) 
DBD 
Non-split grafts 
(n=86) 
DCD 
(n=35) 
p * p ** 
Patient mortality/graft loss overall        
-Cumulative number of events 34 (23.8%) 25 (23.1%) 20 (23.3%) 9 (25.8%) 
-1-year event-free survival rate 86% 87% 87% 84% 0.450 0.427 
-Incidence rate per-100-pt.-yrs. (95% C.I.)  7.5 (6.6–8.8) 6.9 (6.1–8.4) 7.4 (6.2–9.0) 9.4 (7.1–13.9) 0.582 *** 0.586 *** 
Mortality only       
-Cumulative number of events 22 (15.4%) 18 (16.7%) 15 (17.4%) 4 (11.4%) 
-1-year event-free survival rate 90% 90% 90% 89% 0.228 0.183 
-Incidence rate per-100-pt.-yrs. (95% C.I.)  4.5 (4.0–5.2) 4.7 (3.7–6.4) 5.4 (4.5–6.5) 3.9 (3.0–5.4) 0.597 *** 0.454 *** 
Graft loss only       
-Cumulative number of events 16 (11.1%) 11 (10.2%) 7 (8.1%)  5 (14.2%) 
-1-year event-free survival rate 95% 95% 96% 94% 0.113 0.041 
-Incidence rate per-100-pt.-yrs. (95% C.I.)  3.6 (3.1–4.2) 3.1 (2.7–3.7) 2.6 (2.2 – 3.2) 5.2 (3.7–7.7) 0.336 *** 0.170 *** 
* Denotes statistical comparisons between all DBD vs. DCD liver transplants in PSC patients 
** Denotes statistical comparisons between only whole liver DBD grafts vs. DCD transplants in PSC patients 
*** Statistical differences in the clinical event rate between groups assessed by the log rank test (time-dependent endpoints) 
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Table 3: Patient and graft survival in PSC versus non-PSC liver transplantation 
Patient group Mortality  Graft loss Graft loss or mortality 
A) Incidence rates * 
PSC (all) 4.5 (4.0–5.2) 3.6 (3.1–4.2) 7.5 (6.6–8.8) 
PSC DBD 4.7 (3.7–6.4) 3.1 (2.7–3.7) 6.9 (6.1– 8.4) 
PSC DBD  
(Non-split grafts) 
5.4 (4.5 – 6.5) 2.6 (2.2–3.2) 7.4 (6.2–9.0) 
PSC DCD 3.9 (3.0–5.4) 5.3 (4.0–7.7) 9.4 (7.1–13.9) 
Non-PSC (all) 5.6 (5.0–6.3) 1.4 (1.4–1.5) 6.5 (6.2–6.8) 
Non-PSC DBD 5.3 (5.0–5.6) 1.3 (1.2–1.4) 6.3 (5.9–6.7) 
Non-PSC DCD 7.2 (6.4–8.1) 1.7 (1.6–2.0) 8.9 (7.9–10.0) 
B) Risk **  
PSC DCD vs. PSC DBD  0.75 (0.25–2.21) 
p=0.598 
1.69 (0.58–4.95) 
p=0.341  
1.24 (0.56–2.66) 
p=0.583 
PSC DCD vs. PSC DBD  
(Non-split grafts) 
0.66 (0.22–1.99) 
p=0.458 
2.25 (0.68–7.40) 
p=0.182 
1.25 (0.56–2.76) 
p=0.587 
PSC vs. non-PSC (all) 1.30 (0.84–2.03) 
p=0.239 
2.30 (1.30–4.08) 
p=0.004 
0.94 (0.65–1.34) 
p=0.716 
PSC DCD vs. non-PSC DCD 0.57 (0.20–1.58) 
p=0.278 
3.11 (1.04–9.32) 
p=0.043 
1.11 (0.54–2.28) 
p=0.769 
PSC DBD vs. non-PSC DBD 0.83 (0.51–1.35) 
p=0.451 
2.05 (1.04–4.05) 
p=0.038 
1.05 (0.69–1.59) 
p=0.819 
* Values presented per 100-patient-years with 95% confidence intervals in parenthesis. 
** Values presented as hazard ratios with 95% confidence intervals in parenthesis. 
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Figure 1: Non-anastomotic biliary strictures post liver transplantation (PSC) 
 
The incidence of non-anastomotic biliary stricturing disease post liver transplantation 
for PSC is shown for all transplant recipients in [A], and excluding split liver grafts in 
[B]. Hazard ratios for DCD vs. DBD groups: 1.33 (95% CI: 0.53 – 3.38) p=0.540 and 
1.25 (95% CI: 0.48 – 3.26) p = 0.648, for [A] and [B], respectively. Non-anastomotic 
strictures have been included when they occur in the absence of ABO incompatibility, 
chronic rejection and hepatic artery compromise. P values determined via log-rank 
testing. 
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Figure 2: Biliary stricturing disease following liver transplantation in PSC  
 
Kaplan-Meier survivorship estimates illustrating the incidence of post-transplant 
biliary strictures stratified by donor type. The overall incidence of all biliary strictures 
is shown in [A], and more specifically with ischaemic-type biliary strictures (ITBL) 
[B], anastomotic strictures [C] and lesions in keeping with recurrent PSC [D]. P 
values determined via log-rank testing. 
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Figure 3:  Biliary stricturing disease following liver transplantation in PSC 
excluding split liver grafts 
 
Kaplan-Meier survivorship estimates illustrating the incidence of post-transplant 
biliary strictures stratified by donor type and excluding split liver grafts. The overall 
incidence of all biliary strictures is shown in [A], and more specifically for ischaemic-
type biliary strictures (ITBL) [B], anastomotic strictures [C] and lesions in keeping 
with recurrent PSC [D]. P values determined via log-rank testing. 
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Figure 4:  Clinical course following liver transplantation in PSC stratified by 
donor type 
 
Kaplan-Meier survivorship estimates illustrating the incidence of primary endpoints 
stratified by donor type. [A – C] indicate all liver transplants, and [D – F] represent 
exclusion of split liver grafts. Clinical events specified as [A] and [D] all-cause 
mortality, [B] and [E] as graft loss (patients censored at last date of follow-up, or at 
time of death free of re-transplantation); and [C] and [F] indicating graft loss or all-
cause patient mortality combined. P values determined via log-rank testing. 
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Donation after circulatory death liver transplantation does not impact patient or 
graft survival in primary sclerosing cholangitis  
 
• The impact of liver donation after circulatory death (DCD) in transplantation for 
primary sclerosing cholangitis was prospectively evaluated. 
• Operating time, days requiring critical care support, total ventilator days, 
incidence of acute kidney injury, need for renal replacement therapy (RRT) or 
total days requiring RRT were no different between DCD recipients vs. those 
receiving a liver donated after brain death (DBD). 
• DCD vs. DBD transplantation is not associated with increased risk of 
hepatic artery thrombosis or non-anastomotic biliary strictures (NAS) 
overall; however results in an increased incidence of ischaemic-type biliary 
lesions (ITBL) in the first year. 
• The risk of hepatic artery thrombosis is greatest in PSC patients with 
inflammatory bowel disease. 
• Patient and graft survival is not significantly different for transplanted PSC 
patients receiving a DCD vs. DBD liver. 
 
